Gan & Lee Pharmaceuticals Presents Breakthrough Data on Three Innovative Products at American Diabetes Association’s 84th Scientific Session

• Phase 1bThe /2a study evaluated single and two-week doses of GZR18, a novel GLP-1 analogue, in obese/overweight Chinese subjects.

• Preclinical studies evaluated the molecular and pharmacological properties of GZR4, a once-weekly insulin analogue.

• Preclinical studies evaluated and characterized the ultra-long-acting basal insulin GZR33 and its co-formulant GZR101.

Bridgewater, New Jersey, June 17, 2024 /CNW/ — Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) announced today that it has made three presentations related to its investigational drugs at the American Diabetes Association (ADA) Annual Meeting.^[1]) 84^Number Academic sessions. Conferences will be held in person and online. June 21-24, 2024in Orlando, Florida .

All abstracts will be published in the journal Diabetes^® Data from selected studies will be published live on the website. June 22from 12:30pm – 1:30pm EDT In the poster hall.

The abstract and presentation above represent data to be exhibited or made public by Gan & Lee. This press release contains forward-looking statements regarding investigational drugs currently in development by Gan & Lee. It is important to remember that drug development involves risks and there can be no guarantee that future studies will produce results consistent with those presented at the ADA 84th Scientific Session.

references:

[1]ADA 84^Number Scientific Sessions. https://professional.diabetes.org/scientific-sessions

[2]Zhang M, Zhang Y, Peng X, et al. GZR18, a novel long-acting GLP-1 analogue, exhibited favorable pharmacokinetic and pharmacodynamic properties in vitro and in vivo in animal models. Eur J Pharmacol. 2022;928:175107. doi:10.1016/j.ejphar.2022.175107

About Gan & Lee

Gan Li Pharmaceutical developed China’s first domestic insulin analogue. Currently, Gan Li has six main insulin products, five of which are long-acting insulin glargine injections (Basaline).^®), immediate-release lispro injection (Prandilin^™), Rapid-acting Aspart Injection (Lapirin^®), Mixed Protamine Zinc Lispro Injection (25R) (Prandiline^™25), Aspart 30 Injection (Lapirin^®30), and one bottle of human insulin injection – Mixed Protamine Human Insulin Injection (30R) (Similin^®30) The company has two approved medical devices. ChinaReusable insulin injection pen (GanleePen) and disposable pen-type needle (GanleeFine)^®).

in Chinese 2nd Quantity-Based Procurement (Gan & Lee Pharmaceutical ranked second among domestic companies and first overall in the procurement demand for insulin analogues in 2024. The company also has a strong track record in the procurement of disposable pen-type injection needles (Ganley Fine^®) Approved by the U.S. Food and Drug Administration (FDA) in 2020, In 2020, it received GMP inspection approval from the European Medicines Agency (EMA).24. These achievements have significantly improved Gan & Lee’s competitiveness in both the international and domestic markets.

The story continues

Going forward, Gan & Lee will pursue its mission of becoming a world-class pharmaceutical company with comprehensive coverage of diabetes treatment, focus on the treatment of metabolic diseases, cardiovascular diseases and other therapeutic areas, and actively engage in the development of new chemical entities and biological medicines.

Further information
BPRD@ganlee.com (Media)
BD@ganlee.com (Business Development)

View original content to download multimedia:https://www.prnewswire.com/news-releases/gan–lee-pharmaceuticals-to-present-groundbreaking-data-on-three-innovative-products-at-the-american-diabetes-associations-84th-scientific-sessions-302174901.html

SOURCE Gan & Lee Pharmaceuticals

To download multimedia, view the original content: http://www.newswire.ca/en/releases/archive/June2024/17/c9687.html